Confluence welcomes William Taylor Ph.D. as Confluence’s new Director of Biochemistry

Dr. Taylor is an accomplished biochemist and drug discovery scientist with a history of providing strategic leadership and critical analyses across multiple target classes & disease areas. Prior to Confluence Discovery Technologies he spent seventeen years at Vertex Pharmaceuticals where he gained extensive experience in bringing small molecules forward from initial screen through hit-to- lead…

[Read More…]
Aclaris Therapeutics Kinase

Aclaris Therapeutics Acquires Confluence Life Sciences, Inc.

Expands pipeline of medicines for the potential treatment of patients with autoimmune disorders Management to Host Conference Call at 8:30 AM ET today MALVERN, Pa., Aug. 08, 2017 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (“Aclaris”) (NASDAQ:ACRS), a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs…

[Read More…]

A Brief History of Tofacitinib

John LaMattina, FORBES CONTRIBUTOR In the summer of 1993, Dr. Paul Changelian, a scientist in Pfizer’s immune suppression group, was looking for a new way to prevent organ transplant rejection. Paul, always on the lookout for new ideas, particularly ones related to suppressing an overactive immune systems (a hallmark of diseases like psoriasis and rheumatoid…

[Read More…]

Government Collaboration with Industry Helps Drug Development

Innovations: John O’Shea and Arthritis Drug BY ADAM THOMAS You may have seen ads on television for Xeljanz (tofacitinib), a drug used to treat rheumatoid arthritis. Don’t ask me where the name came from. But I can tell you that the drug itself was the brainchild of NIH physician and immunologist John O’Shea. O’Shea, who…

[Read More…]

SAMDI Tech and Confluence Discovery Technologies Announce Partnership Agreement

CHICAGO, IL – September 25, 2015 — SAMDI Tech and Confluence Discovery Technologies are expanding their service offering by entering into a partnership agreement, allowing SAMDI Tech and Confluence Discovery Technologies to mutually promote their respective services. The two companies aim to offer a range of services from drug discovery to preclinical development, combining their…

[Read More…]